Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis

Haematologica

Volumn 96, Issue 7, 2011, Pages 1079-1080

  Wechalekar, Ashutosh D ^a   Gillmore, Julian D ^a   Wassef, Nancy ^b   Lachmann, Helen J ^a   Whelan, Carol ^a   Hawkins, Philip N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; AMYLOIDOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; GLOMERULUS FILTRATION RATE; HEART AMYLOIDOSIS; HUMAN; KIDNEY AMYLOIDOSIS; LETTER; LIGHT CHAIN AMYLOIDOSIS; LIVER AMYLOIDOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN DEFECT; PROTEIN DETERMINATION; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CARDIOMYOPATHIES; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RISK FACTORS;

EID: 79960015354     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.040493     Document Type: Letter

References (11)

1. Pepys MB. Amyloidosis. Annu Rev Med. 2006;57(1):223-41.
2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-60.
3. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186-93.
4. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-5.
5. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal probrain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-7.
6. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854-8.
7. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79(4):319-28.
8. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-64.
9. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-8.
10. Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN. Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis. Blood. 2004;104(11):755.
11. Goodman H, Wechalekar A, Lachmann H, Bradwell A, Hawkins P. Clonal diseaes response and clinical outcome in 229 patients with AL amyloidosis treated with VAD-like chemotherapy. Haematologica. 2005;90(s1):201.